• 1
    Nieswandt B, Aktas B, Moers A, Sach UJH. Platelets in aterothrombosis: lessons from mouse models. J Thromb Haemost 2005; 3: 172536.
  • 2
    Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52: 673751.
  • 3
    Kris-Etherton PM, Lefevre M, Beecher GR, Gross MD, Keen CL, Etherton TD. Bioactive compounds in nutrition and health-research methodologies for establishing biological function: the antioxidant and anti-inflammatory effects of flavonoids on atherosclerosis. Annu Rev Nutr 2004; 24: 51138.
  • 4
    Williams RJ, Spencer JPE, Rice-Evans C. Flavonoids: antioxidants or signaling molecules? Free Radic Biol Med 2004; 36: 83849.
  • 5
    Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci 2004; 96: 22945.
  • 6
    Sarkar FH, Li Y. Cell signalling pathways altered by chemoprotective agents. Mut Res 2004; 555: 5364.
  • 7
    Pignatelli P, Pulcinelli FM, Celestini A, Lenti L, Ghiselli A, Gazzaniga PP, Violi F. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr 2000; 72: 11505.
  • 8
    Freedman JE, Parker C 3rd, Li L, Perlman JA, Frei B, Ivanov V, Deak LR, Iafrati MD, Folts JD. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation 2001; 103: 27928.
  • 9
    Dutta-Roy AK. Dietary components and human platelet activity. Platelets 2002; 13: 6775.
  • 10
    Bucki R, Pastore JJ, Giraud F, Sulpice JC, Janmey PA. Flavonoid inhibition of platelet procoagulant activity and phosphoinositide synthesis. J Thromb Haemost 2003; 1: 18208.
  • 11
    Hubbard GP, Stevens JM, Cicmil M, Sage T, Jordan PA, Williams CM, Lovegrove JA, Gibbins JM. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost 2003; 1: 107988.
  • 12
    Pearson DA, Hiolt RR, Rein D, Paglieroni T, Schmitz HH, Keen CL. Flavanols and platelet reactivity. Clin Dev Immunol 2005; 12: 19.
  • 13
    Arita H, Nakano T, Hanasaki K. Thromboxane A2: its generation and role in platelet activation. Prog Lipid Res 1989; 28: 273301.
  • 14
    Patrono C, García Rodriguez LA, Landolfi R, Bigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 237383.
  • 15
    Szczeklik A, Musiat J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost 2005; 3: 165562.
  • 16
    Patrono C, Coller B, Fitzgerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationship among dose, effectiveness, and side effect: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl.): 234S264S.
  • 17
    Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic target in atherogenesis. Trends Pharmacol Sci 2005; 26: 63944.
  • 18
    Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Naruyima S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991; 349: 61720.
  • 19
    Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994; 269: 1925661.
  • 20
    Habib A, FitzGerald GA, Maclouf J. Phosphorylation of the thromboxane receptor α, the predominant isoform expressed in human platelets. J Biol Chem 1999; 274: 264551.
  • 21
    Huang JS, Ramamurthy SK, Lin X, Le Breton GC. Cell signalling through thromboxane A2 receptors. Cell Signal 2004; 16: 52133.
  • 22
    Boss CL, Richel DJ, Ritsema T, Peppelenbosch MP, Verteeg HH. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004; 36: 1187205.
  • 23
    Thomas DW, Mannon RB, Mannin PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH, Coffman TM. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 1998; 102: 19942001.
  • 24
    Landolfi R, Mowere RL, Steiner M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure–activity relations. Biochem Pharmacol 1984; 33: 152530.
  • 25
    Sheu JR, Hsiao C, Chou PH, Shen MY, Chou DS. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J Agric Food Chem 2004; 52: 44148.
  • 26
    Son DJ, Cho MR, Jin YR, Kim SY, Park YH, Lee SH, Akiba S, Sato T, Yun YP. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 2531.
  • 27
    Tzeng SH, Ko WC, Ko FN, Teng CM. Inhibition of platelet aggregation by some flavonoids. Thromb Res 1991; 64: 91100.
  • 28
    Guglielmone HA, Agnese AM, Nunez Montoya SC, Cabrera JL. Inhibitory effects of sulphated flavonoids isolated from Flaveria bidentis on platelet aggregation. Thromb Res 2005; 115: 495502.
  • 29
    Nakashima KT, Joite T, Nozawa Y. Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses. Mol Pharmacol 1991; 39: 47580.
  • 30
    McNicol A. The effects of genistein on platelet function are due to thromboxane receptor antagonism rather than inhibition of tyrosine kinase. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 37984.
  • 31
    Guerrero JA, Lozano ML, Castillo J, Benavente-Garcia O, Vicente V, Rivera J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost 2005; 3: 36976.
  • 32
    Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 192204.
  • 33
    Lin K, Sadée W, Qullan JM. Rapid measurement of intracellular calcium using a fluorescence plate reader. Biotechniques 1999; 26: 31822.
  • 34
    Chiang N, Tai HH. The role of N-glycosylation of human thromboxane A2 receptor in ligand binding. Arch Biochem Biophys 1998; 352: 20713.
  • 35
    Roger S, Pawlowski M, Habib A, Jandrot-Perrus M, Rosa JP, Bryckaert M. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett 2004; 556: 22735.
  • 36
    Allman-Farinelli MA, Dawson B. Diet and aging: bearing on thrombosis and hemostasis. Semin Thromb Hemost 2005; 31: 1117.
  • 37
    Art ICW, Hollman PCH. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005; 81 (Suppl): 317S25S.
  • 38
    Pastore JJ, Funaki M, Janmey PA, Bucki R. Flavonoid-mediated inhibition of actin polymerization in cold-activated platelets. Platelets 2005; 16: 3627.
  • 39
    Dobrydneva Y, Williams RL, Morris GZ, Blackmore PF. Dietary phytoestrogens and their synthetic structural analogues as calcium channel blockers in human platelets. J Cardiovasc Pharmacol 2002; 40: 399410.
  • 40
    Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 55925.
  • 41
    Börsch-Haubold AG, Ghomashchi F, Pasquet S, Goedert M, Cohen P, Gelb MH, Watson SP. Phosphorylation of cytosolic phospholipase A2 in platelets is mediated by multiple stress-activated protein kinase pathways. Eur J Biochem 1999; 265: 195203.
  • 42
    McNicol A, Jackson ECG. Inhibition of MEK/ERK pathway has no effect on agonist-induced aggregation of human platelets. Biochem Pharmacol 2003; 65: 124350.
  • 43
    Garcia A, Quinton TM, Dorsam RT, Kunapuli SP. Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelet. Blood 2005; 106: 34104.
  • 44
    Rosado JA, Sage SO. Role of the ERK pathway in the activation of store-mediated calcium entry in human platelets. J Biol Chem 2001; 276: 1565965.
  • 45
    Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1998; 1425: 54359.
  • 46
    Picherit C, Dalle M, Neliat G, Lebecque P, Davicco MJ, Barlet JP, Coxam V. Genistein and daidzein modulate in vitro rat uterine contratile activity. J Steroid Biochem Mol Biol 2000; 75: 2018.
  • 47
    Mooro F, Asboth G, Lopez BA. Thromboxane receptor signalling in human myometrial cells. Prostaglandins Other Lipid Med 2002; 67: 3147.
  • 48
    Griffiths AL, Marshall KM, Senior J, Fleming C, Woodward DF. Effect of the oestrous cycle, preganancy, and uterine region on the responsiveness of the isolated mouse uterus to prostaglandin F2{alpha} and the thromboxane mimetic U46619. J Endocrinol 2006; 188: 56977.